SCIENTURE Q1 revenue $56k (+449% YoY); gross margin 95.6%; net loss $3.4M; secures $11M debt

Scienture Holdings, Inc.

2026-Q1 EPS reported -$0.08 vs consensus -$0.22 ▲ beat (+64.3%)

Revenue $56k (+449% YoY); gross profit $54k (+7,900%); gross margin 95.6% vs 6.6%.
Net loss $3.4M vs $3.1M; operating expenses flat at ~$3.56M.
USPTO granted third patent for Arbli (losartan) extending exclusivity through 2041; REZENOPY got Orange Book patent.
GPO agreements for REZENOPY covering 5,000+ institutions; sales force starts June 1, 2026.
Secured $11M non-dilutive debt financing to support commercialization and R&D pipeline.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Scienture Holdings, Inc. reported the three months ended March 31, 2026 results: revenue approximately $56 thousand.

Period: the three months ended March 31, 2026
Revenue: approximately $56 thousand
Result: reported results

Exact text from the filing

business update and reported financial results for the three months ended March 31, 2026. Q1 2026 Financial Highlights Compared to Q1 2025: ● Revenue increased to approximately $56 thousand for the three months ended March 31, 2026, compared to approximately $10 thousand in the prior-year three-month period, representing an increase of approximately 449%

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Scienture Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-025062

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.